Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 416

1.

Commentary: Not only SMART clinically, but translationally!

Pass HI.

J Thorac Cardiovasc Surg. 2019 Oct 3. pii: S0022-5223(19)32114-2. doi: 10.1016/j.jtcvs.2019.09.101. [Epub ahead of print] No abstract available.

PMID:
31677887
2.

Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting.

Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG 3rd, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB 2nd, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH Jr, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang H, Rusch VW, Nowak AK.

J Thorac Oncol. 2019 Oct;14(10):1718-1731. doi: 10.1016/j.jtho.2019.08.012. Epub 2019 Aug 27.

PMID:
31470129
3.

Exosomal miR-16-5p as a target for malignant mesothelioma.

Munson PB, Hall EM, Farina NH, Pass HI, Shukla A.

Sci Rep. 2019 Aug 12;9(1):11688. doi: 10.1038/s41598-019-48133-0.

4.

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI.

CA Cancer J Clin. 2019 Sep;69(5):402-429. doi: 10.3322/caac.21572. Epub 2019 Jul 8. Review.

5.

Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1.

Lignitto L, LeBoeuf SE, Homer H, Jiang S, Askenazi M, Karakousi TR, Pass HI, Bhutkar AJ, Tsirigos A, Ueberheide B, Sayin VI, Papagiannakopoulos T, Pagano M.

Cell. 2019 Jul 11;178(2):316-329.e18. doi: 10.1016/j.cell.2019.06.003. Epub 2019 Jun 27.

PMID:
31257023
6.

Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort.

Amin W, Linkov F, Landsittel DP, Silverstein JC, Bashara W, Gaudioso C, Feldman MD, Pass HI, Melamed J, Friedberg JS, Becich MJ.

Version 3. F1000Res. 2018 Aug 3 [revised 2019 Jan 1];7:1184. doi: 10.12688/f1000research.15512.3. eCollection 2018.

7.

A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce.

Friedberg JS, Culligan MJ, Tsao AS, Rusch V, Sepesi B, Pass HI, Bueno R, Burt B, Sugarbaker DJ, de Perrot M, Adjei AA, Adusumilli PS, Hirsch FR, Malik SM, Harpole DJ Jr.

J Thorac Oncol. 2019 Aug;14(8):1343-1353. doi: 10.1016/j.jtho.2019.04.029. Epub 2019 May 25. Review.

PMID:
31136816
8.

The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Gomez DR, Rimner A, Simone CB 2nd, Cho BCJ, de Perrot M, Adjei AA, Bueno R, Gill RR, Harpole DH Jr, Hesdorffer M, Hirsch FR, Jackson AA, Pass HI, Rice DC, Rusch VW, Tsao AS, Yorke E, Rosenzweig K.

J Thorac Oncol. 2019 Jul;14(7):1172-1183. doi: 10.1016/j.jtho.2019.03.030. Epub 2019 May 22. Review.

PMID:
31125736
9.

A volatile biomarker in breath predicts lung cancer and pulmonary nodules.

Phillips M, Bauer TL, Pass HI.

J Breath Res. 2019 Jun 19;13(3):036013. doi: 10.1088/1752-7163/ab21aa.

PMID:
31085817
10.

Technique, Outcomes With Navigational Bronchoscopy Using Indocyanine Green for Robotic Segmentectomy.

Geraci TC, Ferrari-Light D, Kent A, Michaud G, Zervos M, Pass HI, Cerfolio RJ.

Ann Thorac Surg. 2019 Aug;108(2):363-369. doi: 10.1016/j.athoracsur.2019.03.032. Epub 2019 Apr 10.

PMID:
30980818
11.

When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

Baird AM, Easty D, Jarzabek M, Shiels L, Soltermann A, Klebe S, Raeppel S, MacDonagh L, Wu C, Griggs K, Kirschner MB, Stanfill B, Nonaka D, Goparaju CM, Murer B, Fennell DA, O'Donnell DM, Barr MP, Mutti L, Reid G, Finn S, Cuffe S, Pass HI, Opitz I, Byrne AT, O'Byrne KJ, Gray SG.

Front Endocrinol (Lausanne). 2019 Feb 26;10:89. doi: 10.3389/fendo.2019.00089. eCollection 2019.

12.

The Microbiome in Lung Cancer Tissue and Recurrence-Free Survival.

Peters BA, Hayes RB, Goparaju C, Reid C, Pass HI, Ahn J.

Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):731-740. doi: 10.1158/1055-9965.EPI-18-0966. Epub 2019 Feb 7.

PMID:
30733306
13.

Expert Consensus Document on Pulmonary Metastasectomy.

Handy JR, Bremner RM, Crocenzi TS, Detterbeck FC, Fernando HC, Fidias PM, Firestone S, Johnstone CA, Lanuti M, Litle VR, Kesler KA, Mitchell JD, Pass HI, Ross HJ, Varghese TK.

Ann Thorac Surg. 2019 Feb;107(2):631-649. doi: 10.1016/j.athoracsur.2018.10.028. Epub 2018 Nov 23. Review. No abstract available.

PMID:
30476477
14.

Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503).

Altorki NK, Wang X, Wigle D, Gu L, Darling G, Ashrafi AS, Landrenau R, Miller D, Liberman M, Jones DR, Keenan R, Conti M, Wright G, Veit LJ, Ramalingam SS, Kamel M, Pass HI, Mitchell JD, Stinchcombe T, Vokes E, Kohman LJ.

Lancet Respir Med. 2018 Dec;6(12):915-924. doi: 10.1016/S2213-2600(18)30411-9. Epub 2018 Nov 12.

PMID:
30442588
15.

A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations.

Pastorino S, Yoshikawa Y, Pass HI, Emi M, Nasu M, Pagano I, Takinishi Y, Yamamoto R, Minaai M, Hashimoto-Tamaoki T, Ohmuraya M, Goto K, Goparaju C, Sarin KY, Tanji M, Bononi A, Napolitano A, Gaudino G, Hesdorffer M, Yang H, Carbone M.

J Clin Oncol. 2018 Oct 30:JCO2018790352. doi: 10.1200/JCO.2018.79.0352. [Epub ahead of print]

PMID:
30376426
16.

Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine.

Carbone M, Amelio I, Affar EB, Brugarolas J, Cannon-Albright LA, Cantley LC, Cavenee WK, Chen Z, Croce CM, Andrea A, Gandara D, Giorgi C, Jia W, Lan Q, Mak TW, Manley JL, Mikoshiba K, Onuchic JN, Pass HI, Pinton P, Prives C, Rothman N, Sebti SM, Turkson J, Wu X, Yang H, Yu H, Melino G.

Cell Death Differ. 2018 Nov;25(11):1885-1904. doi: 10.1038/s41418-018-0213-5. Epub 2018 Oct 15. Review.

17.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.

18.

PACIFIC: Time for a surgical IIIA uprising.

Pass HI.

J Thorac Cardiovasc Surg. 2018 Sep;156(3):1249-1254. doi: 10.1016/j.jtcvs.2018.05.059. Epub 2018 Jun 4. No abstract available.

PMID:
30017445
19.

Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma.

Ooki A, Dinalankara W, Marchionni L, Tsay JJ, Goparaju C, Maleki Z, Rom WN, Pass HI, Hoque MO.

Oncogene. 2018 Nov;37(45):5967-5981. doi: 10.1038/s41388-018-0373-2. Epub 2018 Jul 6.

20.

Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis.

Psallidas I, Kanellakis NI, Gerry S, Thézénas ML, Charles PD, Samsonova A, Schiller HB, Fischer R, Asciak R, Hallifax RJ, Mercer R, Dobson M, Dong T, Pavord ID, Collins GS, Kessler BM, Pass HI, Maskell N, Stathopoulos GT, Rahman NM.

Lancet Oncol. 2018 Jul;19(7):930-939. doi: 10.1016/S1470-2045(18)30294-8. Epub 2018 Jun 13.

PMID:
29908990
21.

Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial.

Timmerman RD, Paulus R, Pass HI, Gore EM, Edelman MJ, Galvin J, Straube WL, Nedzi LA, McGarry RC, Robinson CG, Schiff PB, Chang G, Loo BW Jr, Bradley JD, Choy H.

JAMA Oncol. 2018 Sep 1;4(9):1263-1266. doi: 10.1001/jamaoncol.2018.1251.

22.

Sphenopalatine Ganglion Block to Treat Shoulder Tip Pain After Thoracic Surgery: Report of 2 Cases.

Grant GJ, Echevarria GC, Lax J, Pass HI, Oshinsky ML.

A A Pract. 2018 Aug 15;11(4):90-92. doi: 10.1213/XAA.0000000000000746.

PMID:
29634542
23.

Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.

Barash U, Lapidot M, Zohar Y, Loomis C, Moreira A, Feld S, Goparaju C, Yang H, Hammond E, Zhang G, Li JP, Ilan N, Nagler A, Pass HI, Vlodavsky I.

J Natl Cancer Inst. 2018 Oct 1;110(10):1102-1114. doi: 10.1093/jnci/djy032.

24.

Progress in the Management of Malignant Pleural Mesothelioma in 2017.

McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK, Reungwetwattana T, Mao W, Pass HI, Carbone M, Yang H, Peikert T.

J Thorac Oncol. 2018 May;13(5):606-623. doi: 10.1016/j.jtho.2018.02.021. Epub 2018 Mar 8. Review.

25.

Summarizing performance for genome scale measurement of miRNA: reference samples and metrics.

Pine PS, Lund SP, Parsons JR, Vang LK, Mahabal AA, Cinquini L, Kelly SC, Kincaid H, Crichton DJ, Spira A, Liu G, Gower AC, Pass HI, Goparaju C, Dubinett SM, Krysan K, Stass SA, Kukuruga D, Van Keuren-Jensen K, Courtright-Lim A, Thompson KL, Rosenzweig BA, Sorbara L, Srivastava S, Salit ML.

BMC Genomics. 2018 Mar 6;19(1):180. doi: 10.1186/s12864-018-4496-1.

26.

Eighth Edition Staging of Thoracic Malignancies: Implications for the Reporting Pathologist.

Nicholson AG, Tsao MS, Travis WD, Patil DT, Galateau-Salle F, Marino M, Dacic S, Beasley MB, Butnor KJ, Yatabe Y, Pass HI, Rusch VW, Detterbeck FC, Asamura H, Rice TW, Rami-Porta R.

Arch Pathol Lab Med. 2018 May;142(5):645-661. doi: 10.5858/arpa.2017-0245-RA. Epub 2018 Feb 26. Review.

PMID:
29480761
27.

Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma.

Thompson JK, Shukla A, Leggett AL, Munson PB, Miller JM, MacPherson MB, Beuschel SL, Pass HI, Shukla A.

Oncotarget. 2017 Dec 6;9(1):293-305. doi: 10.18632/oncotarget.22968. eCollection 2018 Jan 2.

28.

Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma.

Sato H, Sakaguchi M, Yamamoto H, Tomida S, Aoe K, Shien K, Yoshioka T, Namba K, Torigoe H, Soh J, Tsukuda K, Tao H, Okabe K, Miyoshi S, Pass HI, Toyooka S.

Oncogenesis. 2018 Jan 24;7(1):11. doi: 10.1038/s41389-017-0017-3.

29.

Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer.

Morris S, Vachani A, Pass HI, Rom WN, Ryden K, Weiss GJ, Hogarth DK, Runger G, Richards D, Shelton T, Mallery DW.

Int J Cancer. 2018 Jun 1;142(11):2355-2362. doi: 10.1002/ijc.31245. Epub 2018 Jan 30.

30.

HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.

di Martino S, Amoreo CA, Nuvoli B, Galati R, Strano S, Facciolo F, Alessandrini G, Pass HI, Ciliberto G, Blandino G, De Maria R, Cioce M.

Oncogene. 2018 Mar;37(10):1369-1385. doi: 10.1038/s41388-017-0044-8. Epub 2018 Jan 9.

PMID:
29311642
31.

Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.

Ferdosi S, Rehder DS, Maranian P, Castle EP, Ho TH, Pass HI, Cramer DW, Anderson KS, Fu L, Cole DEC, Le T, Wu X, Borges CR.

J Proteome Res. 2018 Jan 5;17(1):543-558. doi: 10.1021/acs.jproteome.7b00672. Epub 2017 Nov 21.

32.

Prognosis and "granularity": Building on staging foundations?

Pass HI.

J Thorac Cardiovasc Surg. 2018 Jan;155(1):354-355. doi: 10.1016/j.jtcvs.2017.10.032. Epub 2017 Oct 20. No abstract available.

PMID:
29100584
33.

Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.

Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A, Sánchez-Rivera FJ, Subbaraj L, Martinez B, Bronson RT, Prigge JR, Schmidt EE, Thomas CJ, Goparaju C, Davies A, Dolgalev I, Heguy A, Allaj V, Poirier JT, Moreira AL, Rudin CM, Pass HI, Vander Heiden MG, Jacks T, Papagiannakopoulos T.

Nat Med. 2017 Nov;23(11):1362-1368. doi: 10.1038/nm.4407. Epub 2017 Oct 2.

34.

A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA.

Ooki A, Maleki Z, Tsay JJ, Goparaju C, Brait M, Turaga N, Nam HS, Rom WN, Pass HI, Sidransky D, Guerrero-Preston R, Hoque MO.

Clin Cancer Res. 2017 Nov 15;23(22):7141-7152. doi: 10.1158/1078-0432.CCR-17-1222. Epub 2017 Aug 29.

35.

Lepidic Predominant Pulmonary Lesions (LPL): CT-based Distinction From More Invasive Adenocarcinomas Using 3D Volumetric Density and First-order CT Texture Analysis.

Alpert JB, Rusinek H, Ko JP, Dane B, Pass HI, Crawford BK, Rapkiewicz A, Naidich DP.

Acad Radiol. 2017 Dec;24(12):1604-1611. doi: 10.1016/j.acra.2017.07.008. Epub 2017 Aug 24.

PMID:
28844845
36.

Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.

Szymiczek A, Carbone M, Pastorino S, Napolitano A, Tanji M, Minaai M, Pagano I, Mason JM, Pass HI, Bray MR, Mak TW, Yang H.

Oncogene. 2017 Nov 16;36(46):6501-6507. doi: 10.1038/onc.2017.266. Epub 2017 Jul 31.

37.

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.

Chen Z, Gaudino G, Pass HI, Carbone M, Yang H.

Transl Lung Cancer Res. 2017 Jun;6(3):259-269. doi: 10.21037/tlcr.2017.05.06. Review.

38.

Diagnosis and prognosis-review of biomarkers for mesothelioma.

Sun HH, Vaynblat A, Pass HI.

Ann Transl Med. 2017 Jun;5(11):244. doi: 10.21037/atm.2017.06.60. Review.

39.

Clinical validation of a blood-based classifier for diagnostic evaluation of asymptomatic individuals with pulmonary nodules.

Birse CE, Tomic JL, Pass HI, Rom WN, Lagier RJ.

Clin Proteomics. 2017 Jul 5;14:25. doi: 10.1186/s12014-017-9158-9. eCollection 2017.

40.

Quality Initiatives: Baby Steps in the Right Direction.

Pass HI.

Semin Thorac Cardiovasc Surg. 2017 Spring;29(1):102-103. doi: 10.1053/j.semtcvs.2017.03.005. Epub 2017 Mar 31.

PMID:
28683984
41.

Germline BAP1 mutations induce a Warburg effect.

Bononi A, Yang H, Giorgi C, Patergnani S, Pellegrini L, Su M, Xie G, Signorato V, Pastorino S, Morris P, Sakamoto G, Kuchay S, Gaudino G, Pass HI, Napolitano A, Pinton P, Jia W, Carbone M.

Cell Death Differ. 2017 Oct;24(10):1694-1704. doi: 10.1038/cdd.2017.95. Epub 2017 Jun 30.

42.

BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation.

Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, Pellegrini L, Signorato V, Olivetto F, Pastorino S, Nasu M, Napolitano A, Gaudino G, Morris P, Sakamoto G, Ferris LK, Danese A, Raimondi A, Tacchetti C, Kuchay S, Pass HI, Affar EB, Yang H, Pinton P, Carbone M.

Nature. 2017 Jun 22;546(7659):549-553. doi: 10.1038/nature22798. Epub 2017 Jun 14.

43.

Pleural IMRT after Lung-Sparing Cytoreduction for Mesothelioma: Mature Enough to Randomize.

Pass HI.

J Thorac Oncol. 2017 Jun;12(6):919-921. doi: 10.1016/j.jtho.2017.04.013. No abstract available.

44.

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.

Kris MG, Gaspar LE, Chaft JE, Kennedy EB, Azzoli CG, Ellis PM, Lin SH, Pass HI, Seth R, Shepherd FA, Spigel DR, Strawn JR, Ung YC, Weyant M.

J Clin Oncol. 2017 Sep 1;35(25):2960-2974. doi: 10.1200/JCO.2017.72.4401. Epub 2017 Apr 24. Review.

PMID:
28437162
45.

Influence of Extent of Lymph Node Evaluation on Survival for Pathologically Lymph Node Negative Non-Small Cell Lung Cancer.

Becker DJ, Levy BP, Gold HT, Sherman SE, Makarov DV, Schreiber D, Wisnivesky JP, Pass HI.

Am J Clin Oncol. 2018 Aug;41(8):820-825. doi: 10.1097/COC.0000000000000379.

PMID:
28301349
46.

FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model.

Szymiczek A, Pastorino S, Larson D, Tanji M, Pellegrini L, Xue J, Li S, Giorgi C, Pinton P, Takinishi Y, Pass HI, Furuya H, Gaudino G, Napolitano A, Carbone M, Yang H.

J Transl Med. 2017 Mar 15;15(1):58. doi: 10.1186/s12967-017-1158-z.

47.

Introduction: Great Institutions in Cardiothoracic Surgery, Second Edition.

Rosengart TK, Austin EH, Pass HI, Weisel RD.

Semin Thorac Cardiovasc Surg. 2016 Autumn;28(3):609-610. doi: 10.1053/S1043-0679(17)30038-2. No abstract available.

PMID:
28285664
48.

HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma.

Pellegrini L, Xue J, Larson D, Pastorino S, Jube S, Forest KH, Saad-Jube ZS, Napolitano A, Pagano I, Negi VS, Bianchi ME, Morris P, Pass HI, Gaudino G, Carbone M, Yang H.

Oncotarget. 2017 Apr 4;8(14):22649-22661. doi: 10.18632/oncotarget.15152.

49.

Improving the Accuracy of Mesothelioma Diagnosis in China.

Guo Z, Carbone M, Zhang X, Su D, Sun W, Lou J, Gao Z, Shao D, Chen J, Zhang G, Hu J, Chen K, Wang F, Pass HI, Yu H, Napolitano A, Yang H, Mao W.

J Thorac Oncol. 2017 Apr;12(4):714-723. doi: 10.1016/j.jtho.2016.12.006. Epub 2016 Dec 19.

50.

Association of Asbestos Exposure With Malignant Mesothelioma Incidence in Eastern China.

Mao W, Zhang X, Guo Z, Gao Z, Pass HI, Yang H, Carbone M.

JAMA Oncol. 2017 Apr 1;3(4):562-564. doi: 10.1001/jamaoncol.2016.5487. No abstract available. Erratum in: JAMA Oncol. 2017 Apr 1;3(4):568.

Supplemental Content

Support Center